LSALT peptide

DRUG4 trials

Conditions

Acute Kidney InjuryAcute Respiratory Distress SyndromeCOVIDCOVID-19Cardiac SurgeryNone - Study is to Determine Safety in Healthy ParticipantsSars-CoV2Severe Acute Respiratory Syndrome

Early Phase 1

A Phase I Study to Evaluate LSALT Peptide

CompletedNCT03772678

Arch Biopartners Inc.None - Study is to Determine Safety in Healthy Participants

Start: 2019-06-27End: 2020-03-31Updated: 2024-11-29

Phase 2

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

CompletedNCT04402957

Arch Biopartners Inc.Acute Kidney Injury, Acute Respiratory Distress Syndrome, COVID +2

Start: 2020-10-14End: 2022-06-02Updated: 2025-07-09

LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

RecruitingNCT05879432

Arch Biopartners Inc.Acute Kidney Injury, Cardiac Surgery

Start: 2024-03-08End: 2027-08-01Target: 240Updated: 2026-06-12

Phase 3

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

NCT04330690

Sunnybrook Health Sciences CentreCOVID-19

Start: 2020-03-18End: 2024-05-18Target: 2900Updated: 2023-10-13

BMJ Open2024-03-014 citations

Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial

CMAJ Open2022-07-0110 citations

Remdésivir chez les patients hospitalisés pour la COVID-19 au Canada: essai clinique randomisé et contrôlé

Canadian Medical Association Journal2022-05-23

Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial

Canadian Medical Association Journal2022-01-19161 citations

LSALT peptide

Sponsors

Conditions

Early Phase 1

Phase 2

Phase 3

Related Papers